| Autor: |
Chern-En Chiang, MD, PhD, Kwo-Chang Ueng, MD, Ting-Hsing Chao, MD, Tsung-Hsien Lin, MD, PhD, Yih-Jer Wu, MD, PhD, Kang-Ling Wang, MD, Shih-Hsien Sung, MD, PhD, Hung-I Yeh, MD, PhD, Yi-Heng Li, MD, PhD, Ping-Yen Liu, MD, PhD, Kuan-Cheng Chang, MD, PhD, Kou-Gi Shyu, MD, PhD, Jin-Long Huang, MD, PhD, Cheng-Dao Tsai, MD, Huei-Fong Hung, MD, Ming-En Liu, MD, Tze-Fan Chao, MD, PhD, Shu-Meng Cheng, MD, PhD, Hao-Min Cheng, MD, PhD, Pao-Hsien Chu, MD, Wei-Hsian Yin, MD, PhD, Yen-Wen Wu, MD, PhD, Wen-Jone Chen, MD, PhD, Wen-Ter Lai, MD, Shing-Jong Lin, MD, PhD, San-Jou Yeh, MD, Juey-Jen Hwang, MD, PhD, Charles Jia-Yin Hou, MD |
| Jazyk: |
angličtina |
| Rok vydání: |
2021 |
| Předmět: |
|
| Zdroj: |
JACC: Asia, Vol 1, Iss 2, Pp 129-146 (2021) |
| Druh dokumentu: |
article |
| ISSN: |
2772-3747 |
| DOI: |
10.1016/j.jacasi.2021.08.003 |
| Popis: |
Type 2 diabetes is a major threat to human health in the 21st century. More than half a billion people may suffer from this pandemic disease in 2030, leading to a huge burden of cardiovascular complications. Recently, 2 novel antidiabetic agents, glucagon-like peptide 1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, reduced cardiovascular complications in a number of randomized control trials. To integrate new information and to achieve a streamlined process for better patient care, a working group was appointed by the Taiwan Society of Cardiology to formulate a stepwise consensus pathway for these therapies to reduce cardiovascular events in patients with type 2 diabetes. This consensus pathway is complementary to clinical guidelines, acting as a reference to improve patient care. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
